

**Zulresso (brexanolone)
Effective 12/01/2019**

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Brexanolone is a neuroactive steroid gamma-aminobutyric acid (GABA)-A receptor positive allosteric modulator that is chemically identical to endogenous allopregnanolone. Zulresso is FDA indicated for the treatment of postpartum depression (PPD) in adults. Zulresso is given as a continual intravenous infusion over 60 hours.

Coverage Guidelines

Approval of Zulresso will be granted if the member meets all following criteria and documentation has been submitted:

1. The member is 18 years of age or older
2. The medication is being prescribed by or in consultation with a psychiatrist.
3. The member is ≤ 6 months postpartum
4. The member does not have active psychosis
5. The member is not actively breastfeeding at the time of treatment
6. The member must be enrolled in the Zulresso REMS Program prior to administration

Limitations

1. Approvals will be granted for one infusion per pregnancy

References

1. Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc; June 2019
2. Meltzer-Brody S, Colquhoun H, Riesenbergr R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials [published



correction appears in Lancet. 2018;392(10153):1116]. Lancet. 2018;392(10152):1058-1070. doi: 10.1016/S0140-6736(18)31551-4

3. Hoffmann, E Wald J, Colquhoun H. Evaluation of breast milk concentrations following brexanolone iv administration to healthy lactating women: 850. AJOG. 2019;220(S1):S554. doi 10.1016/j.ajog.2018.11.873
4. Stewart DE, Vigod SN. Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics. Annu Rev Med 2019; 70:183
5. Molyneaux E, Howard LM, McGeown HR, et al. Antidepressant treatment for postnatal depression. Cochrane Database Syst Rev 2014; :CD002018

Review History

09/18/2019 – Reviewed. Effective 12/1/2019.

05/19/2021- Reviewed for May P&T; no clinical changes.

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.